GLP‑1s may rewire fuel use

Glucagon-like peptide-1 drugs work like a stronger version of a gut hormone that tells the brain and body a meal has arrived. Researchers now say the medicines may also steer the body to burn more fat, not just eat less. (cell.com) That idea was laid out in a commentary published April 15, 2026 in *Trends in Endocrinology and Metabolism* by researchers including Daniel Drucker, a University of Toronto endocrinologist who helped develop the field. The paper argues that glucagon-like peptide-1 receptor agonists may shift “fuel partitioning,” meaning where the body gets energy, toward fat oxidation. (cell.com) The evidence behind that claim is still early and mixed, but it is not starting from zero. In a 19-day randomized inpatient trial, 35 adults with overweight or obesity who received the experimental glucagon-like peptide-1 and glucagon co-agonist SAR425899 had higher fat oxidation and less metabolic slowdown than the placebo group while both groups followed a 1,000-calorie-per-day deficit diet. (pmc.ncbi.nlm.nih.gov) Glucagon-like peptide-1 receptor agonists were first developed for type 2 diabetes because they increase insulin, reduce glucagon, and slow stomach emptying. Newer reviews say their effects also reach the brain, liver, heart, kidneys, and inflammatory pathways, which helps explain why some benefits do not track neatly with pounds lost. (pmc.ncbi.nlm.nih.gov) That broader view has been moving into clinical practice and regulation. The Food and Drug Administration approved tirzepatide, sold as Zepbound, in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity, and approved semaglutide, sold as Wegovy, in August 2025 for metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis. (fda.gov 1) (fda.gov 2) Semaglutide also has cardiovascular outcome data that go beyond the scale. In the SELECT trial, summarized by the American College of Cardiology, once-weekly semaglutide 2.4 milligrams reduced major adverse cardiovascular events in adults age 45 or older with overweight or obesity and established cardiovascular disease but no diabetes. (acc.org) Researchers are also studying how these drugs intersect with the body’s clock. A March 21, 2026 review in the *International Journal of Molecular Sciences* said glucagon-like peptide-1 signaling is tied to circadian timing and sleep-wake regulation, and that treatment may affect sleep outcomes as well as metabolism. (mdpi.com) Another active line of research looks at the gut microbiome, the community of microbes in the intestines that helps process food and send chemical signals. A 2026 review in the *Canadian Journal of Physiology and Pharmacology* said studies are increasingly examining how glucagon-like peptide-1 receptor agonists, diet, and gut bacteria may interact in obesity treatment. (sciencedirect.com) Doctors say that matters for patients who do not see large weight loss. CNN reported April 15, 2026 that clinical trials suggest about 10% to 15% of people who try glucagon-like peptide-1 drugs are non-responders for substantial weight loss, even as evidence continues to build for heart, liver, and other benefits independent of weight change. (ksl.com) The next step is measurement, not marketing. The April 2026 commentary calls for studies using tools such as indirect calorimetry, which estimates whether the body is burning more carbohydrate or more fat, to test whether the new fuel-use theory holds up across semaglutide, tirzepatide, and related drugs. (cell.com)